Halozyme Therapeutics, Inc. $HALO Stock Holdings Raised by Point Nemo Capital LLC

Point Nemo Capital LLC raised its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 113,450.0% in the 3rd quarter, HoldingsChannel reports. The firm owned 13,626 shares of the biopharmaceutical company’s stock after acquiring an additional 13,614 shares during the quarter. Point Nemo Capital LLC’s holdings in Halozyme Therapeutics were worth $1,504,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of HALO. Congress Asset Management Co. raised its holdings in shares of Halozyme Therapeutics by 85.6% during the third quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock valued at $251,890,000 after purchasing an additional 1,052,509 shares during the period. Bank of America Corp DE acquired a new stake in shares of Halozyme Therapeutics in the 2nd quarter valued at about $214,504,000. William Blair Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics in the 2nd quarter valued at about $196,540,000. Royal London Asset Management Ltd. grew its stake in shares of Halozyme Therapeutics by 12.4% in the 2nd quarter. Royal London Asset Management Ltd. now owns 1,810,815 shares of the biopharmaceutical company’s stock valued at $141,732,000 after buying an additional 200,262 shares during the period. Finally, Jupiter Topco LLC bought a new stake in Halozyme Therapeutics in the 2nd quarter valued at about $105,570,000. 97.79% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

HALO has been the topic of a number of research reports. Zacks Research raised Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 13th. HC Wainwright raised their price objective on Halozyme Therapeutics from $115.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday, October 7th. Wells Fargo & Company boosted their price objective on Halozyme Therapeutics from $95.00 to $110.00 and gave the company an “equal weight” rating in a report on Friday. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. Finally, Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $106.09.

Trending Headlines about Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Q3 revenue rose 39% year over year to $493 million and adjusted EPS of $2.39 beat estimates. Record royalty revenue increased 44% to $341 million. Halozyme also raised its 2026 revenue, royalty, EBITDA and adjusted EPS guidance. Q3 results and guidance
• Positive Sentiment: The FDA approved Johnson & Johnson’s RYBREVANT FASPRO, which uses Halozyme’s ENHANZE technology, for certain patients with advanced head and neck cancer. The expanded use could support future royalties. FDA approval
• Positive Sentiment: Halozyme said its analysis of Medicare’s drug-price negotiation rule indicates zero to minimal impact on royalty revenue through at least 2035, easing a potential long-term concern. Medicare rule assessment
• Neutral Sentiment: Citizens JMP raised its price target to $149 and maintained an outperform rating, while Wells Fargo raised its target to $110 but kept an equal-weight rating—signaling differing views on further upside. Citizens JMP rating
• Negative Sentiment: Despite the earnings beat and higher guidance, reports noted a negative share reaction and questions around the guidance reset, suggesting results may not have met elevated investor expectations. The Merck patent dispute also remains an investor focus. Earnings reaction and guidance questions

Insider Buying and Selling at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $107.43, for a total value of $2,148,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $82,482,605.40. This represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew L. Posard sold 18,996 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $107.74, for a total value of $2,046,629.04. Following the completion of the transaction, the director owned 58,839 shares in the company, valued at $6,339,313.86. This represents a 24.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 125,852 shares of company stock worth $13,538,046. Insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Stock Down 15.7%

Halozyme Therapeutics stock opened at $103.63 on Friday. The firm has a market capitalization of $11.76 billion, a price-to-earnings ratio of 26.37, a price-to-earnings-growth ratio of 0.39 and a beta of 0.92. The firm’s fifty day moving average price is $115.19 and its two-hundred day moving average price is $84.73. Halozyme Therapeutics, Inc. has a 1-year low of $61.22 and a 1-year high of $134.00. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 EPS for the quarter, topping the consensus estimate of $2.30 by $0.09. Halozyme Therapeutics had a net margin of 26.93% and a return on equity of 488.26%. The company had revenue of $492.97 million during the quarter, compared to the consensus estimate of $491.63 million. During the same period in the previous year, the firm posted $1.72 earnings per share. The firm’s revenue for the quarter was up 39.1% on a year-over-year basis. On average, equities research analysts predict that Halozyme Therapeutics, Inc. will post 8.32 earnings per share for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion.

Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

Founded in 1998 and based in San Diego, California, Halozyme serves patients in multiple countries through its own commercial activities and, particularly for ENHANZE-enabled medicines, through its licensing partners.